139 related articles for article (PubMed ID: 28433972)
1. Paraneoplastic jaundice and prostate cancer.
Vieira AC; Alvarenga MJ; Santos JC; Silva AM
BMJ Case Rep; 2017 Apr; 2017():. PubMed ID: 28433972
[TBL] [Abstract][Full Text] [Related]
2. [Bicalutamide].
Taéron C
Rev Infirm; 2010 Mar; (158):47-9. PubMed ID: 20383962
[No Abstract] [Full Text] [Related]
3. Paraneoplastic palmar fasciitis and polyarthritis syndrome in a patient with advanced prostate cancer.
Nadal R; McMahan ZH; Antonarakis ES
Clin Genitourin Cancer; 2013 Dec; 11(4):e15-23. PubMed ID: 23820064
[No Abstract] [Full Text] [Related]
4. Bicalutamide.
Prescrire Int; 2007 Apr; 16(88):67. PubMed ID: 17458049
[TBL] [Abstract][Full Text] [Related]
5. Unusual presentation of advanced prostate cancer masquerading as metastatic and obstructing rectosigmoid cancer.
Chang MD; Davidson AJ; Sutherland T; De Fontgalland D; Johnson D; Wong LM
ANZ J Surg; 2017 May; 87(5):417-419. PubMed ID: 25388794
[No Abstract] [Full Text] [Related]
6. Clinical research of Tashinone IIA combined with endocrine therapy in treating advanced-stage prostate cancer.
Yang J; Wang Z; Song L; Tian F; Yu Z; Li F; Tang L
Cell Biochem Biophys; 2014 Jul; 69(3):503-7. PubMed ID: 24526351
[TBL] [Abstract][Full Text] [Related]
7. Prostate Cancer Presenting with Pruritus and Cholestasis.
Kim YH; Park JM; Kang CD; Seo SO; Lee K; Song G
Korean J Gastroenterol; 2021 Jul; 78(1):59-64. PubMed ID: 34312359
[TBL] [Abstract][Full Text] [Related]
8. [Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program].
Fourcade RO; Richaud P; Coloby P; Malavaud B;
Prog Urol; 2007 Jun; 17(4 Suppl 1):891-910. PubMed ID: 17650746
[No Abstract] [Full Text] [Related]
9. Prostatic adenocarcinoma presenting as isolated inguinal lymphadenopathy.
Doreswamy K; Karthikeyan VS; Nagabhushana M; Shankaranand B
BMJ Case Rep; 2015 Jul; 2015():. PubMed ID: 26153290
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine differentiation of localized prostate cancer during endocrine therapy.
Nemoto K; Tomita Y
Scand J Urol Nephrol; 2007; 41(6):558-60. PubMed ID: 17853028
[TBL] [Abstract][Full Text] [Related]
11. [Prostate cancer - androgen deprivation: intermittent or continuous?].
Wedel SA
Aktuelle Urol; 2014 May; 45(3):180-1. PubMed ID: 24932555
[No Abstract] [Full Text] [Related]
12. Re: Intermittent versus continuous androgen deprivation in prostate cancer.
Taneja SS
J Urol; 2013 Dec; 190(6):2093-4. PubMed ID: 24209518
[No Abstract] [Full Text] [Related]
13. Profound bicalutamide withdrawal syndrome in a hormone-refractory T4N1 prostate cancer permitting both salvage radiotherapy and cessation of hormonal therapy.
Takeshita H; Kawakami S; Fukui I
Int J Urol; 2009 Mar; 16(3):337-8. PubMed ID: 19298352
[No Abstract] [Full Text] [Related]
14. A randomized phase III study of neoadjuvant hormonal therapy in patients with localized prostate cancer.
Warde P; Tsuji D; Bristow R
Clin Genitourin Cancer; 2006 Dec; 5(3):235-7. PubMed ID: 17239279
[TBL] [Abstract][Full Text] [Related]
15. Words of wisdom. Re: Intermittent versus continuous androgen deprivation in prostate cancer.
Sciarra A
Eur Urol; 2013 Dec; 64(6):1014-5. PubMed ID: 24209449
[No Abstract] [Full Text] [Related]
16. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.
Iversen P; Roder MA
Expert Rev Anticancer Ther; 2008 Mar; 8(3):361-9. PubMed ID: 18366284
[TBL] [Abstract][Full Text] [Related]
17. [Hormonal therapy for prostate cancer: methods and prognosis].
Huang BX; Su HC; Cao WL; Sun FK
Zhonghua Nan Ke Xue; 2013 Sep; 19(9):815-9. PubMed ID: 24386861
[TBL] [Abstract][Full Text] [Related]
18. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
Moul JW
Cancer; 2009 Aug; 115(15):3376-8. PubMed ID: 19484788
[No Abstract] [Full Text] [Related]
19. Urological cancer: walking the tightrope of survival and quality of life with ADT.
Resnick MJ
Nat Rev Clin Oncol; 2013 Jun; 10(6):307-8. PubMed ID: 23648827
[No Abstract] [Full Text] [Related]
20. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
